> Download the full agenda for the 2009 Commercialization Summit

The 2009 AmerisourceBergen Specialty Group Commercialization Summit will feature a day and a half of industry analysis, case study discussions and networking opportunities. Featured speakers this year include:

Jeffrey Ma - Member of the Famed MIT Blackjack Team, Subject of the New York Times Bestseller Bringing Down the House

Using the undeniable power of numbers, Jeffrey Ma has helped spearhead what BusinessWeek calls “The New Age of Numbers.” The famous number-crunching, MIT whiz kid who took Vegas by storm, Ma is the subject of both a New York Times bestseller, Bringing Down the House, and the movie 21, starring Kevin Spacey. In his presentation, he will draw on his extraordinary life and work to show how to harness the power of rational, quantitative analysis to make smarter business decisions.

Don Reynolds — Real-world Economist, Futurist and Past Pension Board Chairman with Responsibility for More than $100 Billion in Investments

Don’s prominence as a forecaster began with his “astonishingly accurate” predictions on oil prices for the Texas State Legislature. He then served 11 years as chairman of the investment advisory board of a $22 billion trust fund and was appointed as pension board chairman with responsibility for $100 billion in investments. He has personally advised some of the wealthiest families in America. Today, he focuses his research on long-term global, economic, demographic and technology trends—and how those forces interplay to create enormous problems and opportunities.

***

Critical Strategies for Pharmaceutical Product Success

In addition to our featured presentations, the 2009 Commercialization Summit will provide content developed to address specific issues impacting specialty pharmaceutical manufacturers:

• Healthcare policy changes, impact and strategies
• The new compendia landscape
• Increasing patient adherence for enhanced product success
• Comparative effectiveness: The path from theory to reality
• Changing expectations of payers with manufacturers and providers
• REMS and patient access